CORRESPONDENCE

Mutations in *PLA2G6* and the riddle of Schindler disease s K Westaway, A Gregory, S J Hayflick

J Med Genet 2007;44:e64 (http://www.jmedgenet.com/cgi/content/full/44/1/e64). doi: 10.1136/jmg.2006.044966

Where and the end of the end of

We recently identified mutations in the calcium-independent phospholipase A_2 gene, *PLA2G6*, in infantile neuroaxonal dystrophy (INAD).⁴ INAD is characterised by progressive motor and sensory impairment, with pathological evidence of distended axons, termed "spheroids", in the central and peripheral nervous systems. Spheroids are also seen in Schindler disease but in only a subset of patients. Indeed, Schindler disease has been categorised as a neuroaxonal dystrophy. On the basis of their common clinical and pathological features and the proximity of *PLA2G6* to *NAGA* on chromosome 22, we hypothesise that mutations in *PLA2G6* account for the childhood neurodegenerative phenotype that occurs in a subset of patients with Schindler disease.

How might mutations in two genes arise in multiple patients with NAGA deficiency and neuroaxonal dystrophy? Only three patients with Schindler disease are documented to have both spheroids and *NAGA* mutations, and all are related. Schindler original patients had consanguineous parents, and the third is "consanguineous with the first patients".³ All three are homozygous for the same *NAGA* mutation⁵; thus, these patients are homozygous through identity by descent. We hypothesise that they carry two chromosomes 22 that bear deleterious mutations in both the *NAGA* and *PLA2G6* genes. Deficiency of α -NAGA

accounts for their biochemical phenotype. Defective *PLA2G6* underlies their neurodegenerative disease, which is clinically and pathologically indistinguishable from that of patients with classic INAD. Most patients with α -NAGA deficiency do not show early psychomotor regression because their disease is caused by mutations in *NAGA* only.

Testing of the samples from patients with Schindler disease (which are unavailable to us) for mutations in *PLA2G6* should resolve the question of whether Schindler disease is, as Bakker *et al*³ suggest, an "accidental occurrence of two monogenic diseases". We propose that it is.

Authors' affiliations

S K Westaway, A Gregory, S J Hayflick, Departments of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, Oregon, USA

Competing interests: None declared.

Received 19 June 2006 Revised 27 June 2006 Accepted 1 July 2006

REFERENCES

- Schindler D, Bishop DF, Wallace S, et al. Neuroaxonal dystrophy due to lysosomal alpha-N-acetylgalactosaminidase deficiency. N Engl J Med 1989;320:1735–40.
- 2 Bakker HD, de Sonnaville MLCS, Vreken P, et al. Human α-Nacetylgalactosaminidase (α-NAGA) deficiency: no association with neuroaxonal dystrophy? Eur J Hum Genet 2001;9:91–6.
- 3 Keulemans JL, Reuser AJ, Kroos MA, et al. Human alpha-Nacetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet 1996;33:458–64.
- 4 Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752–4.
- 5 Wang AM, Schindler D, Desnick R. Schindler disease: the molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy. J Clin Invest 1990;86:1752–6.